6:41 AM
Mar 04, 2019
 |  BC Extra  |  Company News

Biogen to acquire ophthalmology gene therapy play Nightstar

Editor's Note: This article was updated on Mar 07, 2019 at 10:43 AM PST

Gene therapy platforms continue to capture the interest of large biopharma, with Biogen the latest to announce a deal. The bellwether said early Monday that it will acquire ophthalmology gene therapy company Nightstar for $877 million, marking the second major gene therapy acquisition in the past week.

On Feb. 25, Roche announced it would acquire gene therapy play Spark Therapeutics Inc. (NASDAQ:ONCE) for $4.8 billion (see "Spark Gives Roche Beachhead in Gene Therapy").


Read the full 359 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >